$599
Biocon CY Q1 ’19 (FY Q4 ’19) Earnings Update
Biocon hosted its CY Q1 ’19 (FY Q4 ’19) earnings call and briefly discussed its biosimilar insulin program including bs-glargine and bs-aspart. Below, FENIX provides highlights and insights from the call.